Literature DB >> 27255054

Investment case concepts in leprosy elimination: A systematic review.

Anuj Tiwari, Jan Hendrik Richardus.   

Abstract

INTRODUCTION: Leprosy continues to be a global public health problem, but draws less attention because 'prevalence based elimination' has been misinterpreted as eradication. The ongoing transmission of M. leprae has renewed interest in complete elimination. The aim of our study is to review systematically the literature regarding the elimination of leprosy, and to assess this information on its applicability for defining a Leprosy Elimination Investment Case (LEIC) based on Eradication Investment Case guidelines.
METHODOLOGY: A literature search was conducted using the MeSH subheadings and synonyms of leprosy. A total of 1007 articles were considered and 112 were included in the final selection. The search focused on the literature covering leprosy elimination and its public health aspects. The LEIC framework was adapted from an existing "Guide to Preparing an Eradication Investment Case".
RESULTS: The LEIC framework provided 11 topics under which information was synthesized from the literature. The fields were categorised under sections: 1) Proposed investment; 2) Rationale for investing; 3) Issues to consider when moving from control to eradication; 4) Management and governance. Scanty quantitative data are available for developing a LEIC, particularly regarding disease burden, and new interventions that could contribute to elimination are not yet applied routinely. DISCUSSION: For monitoring global elimination, it is necessary to measure disease burden comprehensively, and contact centered preventive interventions should be part of a global elimination strategy. The biological and technical feasibility of elimination is not certain and advanced microbiological and operational research is necessary to understand transmission better. The current WHO road map for leprosy elimination is too vague and needs further structuring through a thoroughly prepared LEIC.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27255054

Source DB:  PubMed          Journal:  Lepr Rev        ISSN: 0305-7518            Impact factor:   0.537


  6 in total

1.  Household expenditure on leprosy outpatient services in the Indian health system: A comparative study.

Authors:  Anuj Tiwari; Pramilesh Suryawanshi; Akash Raikwar; Mohammad Arif; Jan Hendrik Richardus
Journal:  PLoS Negl Trop Dis       Date:  2018-01-04

2.  Molecular, immunological and neurophysiological evaluations for early diagnosis of neural impairment in seropositive leprosy household contacts.

Authors:  Diogo Fernandes Dos Santos; Matheus Rocha Mendonça; Douglas Eulálio Antunes; Elaine Fávaro Pípi Sabino; Raquel Campos Pereira; Luiz Ricardo Goulart; Isabela Maria Bernardes Goulart
Journal:  PLoS Negl Trop Dis       Date:  2018-05-21

3.  Leprosy services in primary health care in India: comparative economic cost analysis of two public-health settings.

Authors:  Anuj Tiwari; David J Blok; Pramilesh Suryawanshi; Akash Raikwar; Mohammad Arif; Jan Hendrik Richardus
Journal:  Trop Med Int Health       Date:  2018-12-06       Impact factor: 2.622

Review 4.  Setting targets for HIV/AIDS-What lessons can be learned from other disease control programmes?

Authors:  Tazeem Bhatia; Jamie Enoch; Mishal Khan; Sophie Mathewson; David Heymann; Richard Hayes; Osman Dar
Journal:  PLoS Med       Date:  2019-02-04       Impact factor: 11.069

5.  A comprehensive research agenda for zero leprosy.

Authors:  Peter Steinmann; Courtenay Dusenbury; David Addiss; Fareed Mirza; W Cairns S Smith
Journal:  Infect Dis Poverty       Date:  2020-11-12       Impact factor: 4.520

6.  World Health Organization (WHO) antibiotic regimen against other regimens for the treatment of leprosy: a systematic review and meta-analysis.

Authors:  Maria Lazo-Porras; Gabriela J Prutsky; Patricia Barrionuevo; Jose Carlos Tapia; Cesar Ugarte-Gil; Oscar J Ponce; Ana Acuña-Villaorduña; Juan Pablo Domecq; Celso De la Cruz-Luque; Larry J Prokop; Germán Málaga
Journal:  BMC Infect Dis       Date:  2020-01-20       Impact factor: 3.090

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.